Are there dangers in biologic dose reduction strategies?

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 742-746

  Chan, Christopher K Y ^a   Holroyd, Christopher R ^a   Mason, Alice ^a   Zarroug, Jalaa ^b   Edwards, Christopher J ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Biologic; Dose; Reduction; Risk; Taper

Indexed keywords

BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL FACTOR;

CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; HUMAN; IMMUNOGENICITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; DISEASE COURSE; DOSE RESPONSE; RISK FACTOR; TIME FACTOR;

BIOLOGICAL FACTORS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK FACTORS; TIME FACTORS;

EID: 84962593697     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.03.013     Document Type: Review

References (24)

1. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Ustianowski A.P., Helbert M., et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:1810-1814. 10.1136/ard.2011.152769.
2. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528. 10.1136/ard.2009.118935.
3. Ding T., Ledingham J., Luqmani R., Westlake S., Hyrich K., Lunt M., et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010, 49:2217-2219. 10.1093/rheumatology/keq249a.
4. Vogelzang E., Kneepkens E.L., Nurmohamed M.T. A concentration-effect curve of adalimumab in patients with psoriatic arthritis. Ann Rheum Dis 2014, 73(Suppl. 2):88-89.
5. Jani M., Barton A., Warren R.B., Griffiths C.E.M., Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology 2013, 53:213-222. 10.1093/rheumatology/ket260.
6. ten Wolde S., Hermans J., Breedveld F.C., Dijkmans B.A. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997, 56:235-239.
7. Huizinga T.W.J., Conaghan P.G., Martin-Mola E., Schett G., Amital H., Xavier R.M., et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2015, 74:35-43. 10.1136/annrheumdis-2014-205752.
8. Nishimoto N., Amano K., Hirabayashi Y., Horiuchi T., Ishii T., Iwahashi M., et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2013, 7595:1-9. 10.1007/s10165-013-0894-z.
9. Tanaka Y., Hirata S., Kubo S., Fukuyo S., Hanami K., Sawamukai N., et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015, 74:389-395. 10.1136/annrheumdis-2013-204016.
10. Takeuchi T., Matsubara T., Ohta S., Mukai M., Amano K., Tohma S., et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology (Oxford) 2015, 54:683-691. 10.1093/rheumatology/keu338.
11. N V.H., Aa D.B., Jacobs W., A V.D.M., Jwj B., Vollenhoven V., et al. Down-titration and Discontinuation Strategies of Tumor Necrosis Factor-blocking Agents for Rheumatoid Arthritis in Patients with Low Disease Activity (Review) Down-titration and Discontinuation Strategies of Tumor Necrosis Factor-blocking Agents for rhe 2014, 10.1002/14651858.CD010455.pub2.Copyright.
12. Smolen J.S., Nash P., Durez P., Hall S., Ilivanova E., Irazoque-Palazuelos F., et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet (Lond. Engl.) 2013, 381:918-929. 10.1016/S0140-6736(12)61811-X.
13. Fautrel B., Pham T., Alfaiate T., Gandjbakhch F., Foltz V., Morel J., et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS St. Ann Rheum Dis 2016, 75:59-67. 10.1136/annrheumdis-2014-206696.
14. Marks J.L., Holroyd C.R., Dimitrov B.D., Armstrong R.D., Calogeras A., Cooper C., et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?. Arthritis Care Res 2015, 67:746-753. 10.1002/acr.22552.
15. van Vollenhoven R.F., Ostergaard M., Leirisalo-Repo M., Uhlig T., Jansson M., Larsson E., et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2015, 75:1-7. 10.1136/annrheumdis-2014-205726.
16. Moghadam M.G., Vonkeman H.E., Ten Klooster P.M., Tekstra J., van Schaardenburg D., Starmans-Kool M., et al. Stopping tumor necrosis factor-inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open-label controlled trial. Arthritis Rheumatol (Hoboken) 2016, 10.1002/art.39626.
17. Goekoop-Ruiterman Y.P.M., De Vries-Bouwstra J.K., Allaart C.F., Van Zeben D., Kerstens P.J.S.M., Hazes J.M.W., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390. 10.1002/art.21405.
18. van den Broek M., Klarenbeek N.B., Dirven L., van Schaardenburg D., Hulsmans H.M., Kerstens P.J., et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011, 70:1389-1394. 10.1136/ard.2010.147751.
19. Galloway J.B., Mercer L.K., Moseley A., Dixon W.G., Ustianowski A.P., Helbert M., et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013, 72:229-234. 10.1136/annrheumdis-2011-201108.
20. Markusse I.M., Dirven L., Gerards A.H., van Groenendael J.H.L.M., Ronday H.K., Kerstens P.J.S.M., et al. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Res Ther 2015, 17:232. 10.1186/s13075-015-0730-2.
21. Westlake S.L., Colebatch A.N., Baird J., Curzen N., Kiely P., Quinn M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:518-531. 10.1093/rheumatology/keq316.
22. Vincent F.B., Morand E.F., Murphy K., Mackay F., Mariette X., Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013, 72:165-178. 10.1136/annrheumdis-2012-202545.
23. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563. 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.
24. Breban M., Ravaud P., Claudepierre P., Baron G., Henry Y.-D., Hudry C., et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008, 58:88-97. 10.1002/art.23167.